Brought to you by 
Clovis gets global license to Pfizer's PARP inhibitor PF01367338
06 May 2020
Executive Summary
Pfizer Inc. has licensed Clovis Oncology Inc. (developing therapeutics and diagnostics for cancer) worldwide rights to develop and commercialize oral and IV formulations of its Phase I/II potent poly (ADP-ribose) polymerase (PARP) inhibitor PF01367338 for solid tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clovis gets global license to Pfizer's PARP inhibitor PF01367338
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice